Deferiprone

證據等級: L5

預測適應症: 9 個

Deferiprone: From Iron Chelation Therapy to Hepatic Porphyria

One-Sentence Summary

Deferiprone is an oral iron chelator; based on data within this evidence pack, its established clinical role is managing transfusional iron overload (e.g., in beta-thalassemia — see rank 8 candidate below), though the formal original indication and TFDA label are not documented in this pack. The TxGNN model's top-ranked new prediction for this drug is Hepatic Porphyria, with a 99.20% prediction score — but no clinical trials and no literature currently support this specific direction, and the model's own mechanistic rationale flags the biological link as weak.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (`original_indications` empty; see DG001/DG002). Drug class context from pack: oral iron chelator, established use in transfusional iron overload (see beta-thalassemia candidate, rank 8)
Predicted New Indication	Hepatic Porphyria
TxGNN Prediction Score	99.20%
Evidence Level	L5 (model prediction only, no clinical or literature evidence)
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (original_moa: [Data Gap], flagged as DG002 in this pack). Based on information present elsewhere in this evidence pack (rank 8 rationale), deferiprone is an oral tris-hydroxypyridinone iron chelator that penetrates cell membranes, binds free ferric iron, and promotes its urinary excretion — a mechanism directly relevant to iron-overload states such as those seen in chronically transfused patients.

For hepatic porphyria, however, the model's own repurposing rationale explicitly states the mechanistic link is weak: hepatic porphyria arises from enzyme deficiencies in the heme biosynthesis pathway causing accumulation of toxic intermediates, not from tissue iron overload. Deferiprone's iron-chelating action has no established pathophysiological connection to this disease process. This top-ranked candidate therefore reflects a statistical similarity signal from TxGNN, not a mechanism- or evidence-based hypothesis.

Note on this multi-candidate pack: Among the 9 predicted indications evaluated for deferiprone, only beta-thalassemia with other manifestations (rank 8) is supported by actual literature (2 publications, evidence level L3) and carries a "Proceed with Guardrails" recommendation — consistent with deferiprone's real-world use in transfusion-dependent iron overload. The top-ranked-by-score candidate (hepatic porphyria, this report's subject) has neither trials nor literature and is recommended Hold. Reviewers should weigh evidence strength, not score rank alone, when prioritizing candidates from this pack.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Germany Market Information

No German/Taiwan marketing authorizations are currently held for this drug (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

(Note: key_warnings, contraindications, and DDI data are all marked as data gaps in this pack. DG001 — missing TFDA package insert warnings/contraindications — is flagged as a Blocking severity gap, meaning it currently prevents formal S1 safety review for any indication under this drug.)

Conclusion and Next Steps

Decision: Hold

Rationale: The hepatic porphyria prediction has no supporting clinical trials or literature, and the model's own mechanistic rationale rates the biological plausibility as weak (L5, no direct disease-mechanism overlap with iron chelation). Combined with a Blocking-severity TFDA safety data gap for the drug overall, this candidate cannot advance past initial screening.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — required to clear the Blocking gap (DG001) before any S1 safety review
Documented mechanism of action (DG002) to properly evaluate mechanistic plausibility across all candidate indications
Preclinical or mechanistic studies specifically linking iron chelation to heme biosynthesis pathway disorders, if this indication is to be pursued further
As an alternative, consider redirecting evaluation resources to the beta-thalassemia with other manifestations candidate (rank 8), which already has literature support and a "Proceed with Guardrails" status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.